CorMedix, Inc. (NYSE MKT: CRMD) is a commercial-stage biopharmaceutical company seeking to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases. The company’s first commercial product, Neutrolin®, is currently marketed in Europe as a catheter lock solution for the prevention of catheter-related bloodstream infections in hemodialysis, oncology and critical care patients. In the coming months, CorMedix plans to expand commercial distribution of Neutrolin into the United States, Asia, the Middle East, South America and Africa following appropriate regulatory approval.

In June, CorMedix took a significant step toward the eventual commercialization of its innovative product in the United States when it received positive feedback from the FDA regarding a second pivotal clinical trial protocol. This protocol is designed to assess Neutrolin as a catheter lock solution in oncology patients who require total parental nutrition. Previously, the FDA also reviewed the company’s phase III clinical trial protocol to evaluate the use of Neutrolin in hemodialysis patients. With this feedback received, CorMedix expects to initiate the corresponding clinical trials in the fourth quarter of this year. Since the company’s product received fast track designation earlier this year, these trials will be eligible for priority review of FDA submissions and accelerated clinical results in the future.

“CorMedix is thankful for the valuable feedback provided by the FDA, and we are encouraged by their continued enthusiasm and support of Neutrolin,” Randy Milby, chief executive officer of CorMedix, stated in a news release. “We are optimistic that this trial will further our efforts to bring Neutrolin to market in the United States so that more patients can benefit from its use.”

Following FDA approval, Neutrolin will provide CorMedix with access to an underserved market within the biopharmaceutical industry. According to the company’s data, central venous catheters are the most frequent cause of healthcare-associated bloodstream infections, accounting for approximately 25 percent of the 1.7 million recorded hospital infections each year. Among these infections, approximately 20 percent are fatal, further demonstrated the immense market potential of the company’s product.

For prospective shareholders, CorMedix’s continued progress toward commercialization of Neutrolin in the United States could foreshadow an opportunity for the company to realize strong financial growth in the months to come. Look for CorMedix to continue preparing for the initiation of two phase III clinical trials moving forward.

For more information, visit www.cormedix.com

Venaxis, Inc. (NASDAQ: APPY) is an in vitro diagnostic company focused on the development and commercialization of its leading product candidate, the APPY1™ Test. This novel blood-based diagnostic test is designed to aid in the evaluation of patients at low risk for acute appendicitis, allowing physicians to more effectively manage the large number of children and adolescents who enter hospital emergency departments with abdominal pain. Currently, determining if a patient requires emergency surgery for appendicitis normally requires diagnostic CT imaging, which is both expensive and time-intensive. In cases where imaging capacity is limited, patients are often admitted to the hospital in order to avoid the risk of appendicitis rupture at home, which adds significant cost for both patients and hospitals.

When fully commercialized, the APPY1 Test will provide physicians with a more cost-effective approach to diagnosing appendicitis. According to the Centers for Disease Control and Prevention, physicians ordered an estimated 7.5 million blood tests for abdominal pain in 2010, and approximately one million were performed on patients less than 21 years old. Statistically, these young patients have the highest risk of long-term health effects resulting from CT imaging. For this reason, Venaxis is initially developing the APPY1 Test for pediatric, adolescent and young adult patients.

In January, the FDA determined that the Appy1 Test did not meet the criteria for substantial equivalence based upon data and information submitted by Venaxis. As of the company’s latest business update in June, FDA clearance process and status for the APPY1 Test was still under evaluation. However, Venaxis is continuing to advance toward the commercialization of its innovative product through a limited launch in select European countries scheduled to begin in the coming months.

“The FDA decision is very disappointing,” Steve Lundy, president and chief executive officer of Venaxis, stated in a January news release. “We believe that the strong clinical trial results we achieved and the additional clinical utility information we provided to the FDA in response to its requests for additional information were compelling, and we intend to continue to work with the FDA to advance the progress of a blood-based diagnostic test to assist in the evaluation of appendicitis.”

Despite beginning the year with a disappointing FDA ruling, Venaxis has made significant strides toward improved financial results through the continued development of the APPY1 Test. For prospective shareholders, Venaxis’s unwavering commitment to the development of innovative alternatives to current appendicitis diagnostic techniques could provide a platform upon which to realize sustainable returns in the years to come.

For more information, visit www.venaxis.com

ClearSign Combustion Corp. (NASDAQ: CLIR) designs, develops and markets technologies that improve key performance characteristics of combustion systems – including emissions and operational performance, energy efficiency and overall cost-effectiveness. The company’s patent-pending Duplex™ and Electrodynamic Combustion Control™ (ECC) platform technologies are designed to dramatically improve the performance of the world’s commercial, industrial and utility combustion systems. By providing simple retrofit strategies that are utilized during combustion, ClearSign allows its customers to optimize performance at a fraction of the cost of more common legacy after-treatment methods.

The potential market for ClearSign’s products is immense. Nearly two-thirds of global energy consumption can be attributed to the combustion of hydrocarbons and other fuels in boilers, furnaces, kilns and turbines. In the United States, these power generating processes account for more than 50 quadrillion British thermal units (BTUs) of energy each year. As a result of this scale, even modest increases in efficiency can lead to massive savings across a broad range of markets – including the chemical, petrochemical, refinery, power and commercial boiler industries.

In the first quarter of 2015, ClearSign achieved several significant commercial milestones that could set the stage for considerable industry growth in the future. In particular, the company validated the effectiveness of its Duplex technology by demonstrating a meaningful reduction in energy consumption in a field demonstration at Aera Energy in California. Following these results, the company was invited to present its technical results to environmental regulators in Texas, providing a platform upon which to expand its market share in the Lone Star State, which currently refines more than one quarter of the nation’s gasoline. The company also presented its technology to experts from the American Petroleum Institute (API) in April.

“The refinery and petrochemical segment is a significant market opportunity for ClearSign,” Steve Pirnat, chairman and chief executive officer of ClearSign, stated in a news release. “We are very encouraged by the positive feedback we received from the API membership and also believe that successful installations at the two refinery projects already in our trial order backlog will build further confidence and interest in Duplex technology for refinery applications.”

For prospective investors, ClearSign’s recent progress toward industry growth could foreshadow an opportunity for the company to realize improved financial results in the months to come. Look for ClearSign to leverage the strong performance of its proprietary technologies in order to promote sustainable returns moving forward.

For more information, visit www.clearsign.com

Today before the opening bell, Dominovas Energy announced that it has established critical relationships with financing partners included within the scope of the Power Africa Initiative. Using its status as a Private Sector Partner, Dominovas Energy said it looks forward to exercising its direct access to Power Africa’s committed government, public and private sector lenders, such as Goldman Sachs (NYSE: GS), Barclays (NYSE: BCS) and Standard Bank, and global development finance institutions (DFIs), such as the Overseas Private Investment Corporation (OPIC) and the Africa Development Bank (AfDB). GE Capital veteran Eric Fresh will be responsible for leading and managing the company’s project finance and investment activities, its capital investment, and deployment programs, as well as the coordination with Power Africa Partners.

“As a member of the Power Africa Initiative, we have a vested interest in ensuring the Initiative’s success by employing all of its available resources, including engaging its committed financing partners in dialogue about our project level capital needs,” said Mr. Fresh, Senior VP, Finance & Investment, in a recent interview. “With a captive audience of highly specialized project finance lenders and investors, we have an amazing opportunity to secure the type of structured equity and debt financing necessary to successfully deploy our RUBICONTM systems throughout sub-Saharan Africa.”

According to Mr. Fresh, “When domestic financial institutions in Africa lend at rates in excess of 18-20% per annum, most, if not all, large infrastructure projects in Africa require at least minimal involvement from the DFI community to access sufficiently flexible financing solutions to fund projects in countries with challenging credit profiles. While offering some level of increased comfort, the credit solutions provided by DFIs enhance the bankability and profitability of power projects in Africa for investors and private sector lenders by structuring credit facilities with longer tenors and lower interest rates; and by offering political risk insurance (PRI) and partial risk guarantees (PRG) through MIGA and the World Bank, respectively, to mitigate non-commercial risks.”

With respect to financing electricity generating systems that fall under the Power Africa Initiative in developing / emerging markets of sub-Saharan Africa, these affiliated financial institutions have committed to support the initiative by catalyzing private investment. Mr. Fresh added, “The institutions with which Dominovas Energy is actively engaged in project financing discussions create tremendous options in terms of financing power systems, on a multi-megawatt scale. For instance, OPIC can provide debt financing and political risk insurance to spur development investment.”

“Just as we have established a world-class team of OEM partners, Dominovas Energy now has a strong base of support from strategic financing partners capable of delivering billions of dollars of project capital in sub-Saharan Africa and beyond, over the next 5-10 years.”

Having the ability to identify and engage viable financial institutions provides Dominovas Energy the opportunity to capture future revenue streams, as supported by its executed and guaranteed power purchase agreements (PPAs). The value derived for project finance-based platforms is recognized by virtue of signed and executed PPAs, which define both costs and margin for delivery of electricity. As such, Dominovas Energy continues to exude confidence and excitement regarding its prospects for delivering on its mandate of creating clean, commercially-viable, reliable, and sustainable energy solutions to global and bankable emerging markets.

For more information, visit www.dominovasenergy.com

Let us hear your thoughts: Dominovas Energy Corp. Message Boards

Galenfeha today announced that its stored energy products will be offered through ABB Group (NYSE: ABB), a global leader in power and automation technologies. With a market cap of $45 billion, ABB is one of the largest engineering companies as well as one of the largest conglomerates in the world.

Galenfeha’s proprietary products include the GLFH-30 LiFePO4 battery system; DLP Solar Powered Chemical Injection Pump; DLP Pneumatic Chemical Injection Pump; and the iWaV Control System. The company is based in Ft. Worth, Texas, with manufacturing and distribution facilities in Shreveport, Louisiana.

“It is a privilege to be represented in ABB’s product offerings,” stated Mr. Lucien Marioneaux Jr., Galenfeha’s president and CEO. “This affiliation will enable Galenfeha to significantly broaden its customer base locally, nationally, even internationally, and we couldn’t be more pleased with this development.”

For more information, visit www.galenfeha.com

Let us hear your thoughts: Galenfeha, Inc. Message Board

Bulova Technologies Group, through its three operating subsidiaries, Bulova Technologies Europe LLC, Bulova Technologies Machinery LLC and Bulova Technologies Advanced Products LLC, engages in the brokerage of ammunition and industrial machine tools and equipment throughout North America. The company, which is registered with the United States Department of State Directorate of Defense Trade Controls, has an extensive history of large scale defense contracts for munitions, weapons systems and combat systems, in addition to serving as an importer of small caliber ammunition for the U.S. commercial marketplace. As a certified broker, Bulova is able to arrange for the movement of military articles across friendly borders, providing the U.S. military and allied governments with the materials needed to obtain an overwhelming edge over enemy forces.

In recent months, Bulova has taken major steps toward extending its reach into promising new markets. In January, the company announced the formation of Bulova Technologies Heath Care Products LLC, which is currently pursuing the development and marketing of high-tech medical products, as well as negotiating for products which provide promising benefits. In March, Bulova continued its expansion efforts through the announcement of a joint venture to enter the cyber security marketplace. Through this partnership, the company will market the innovative Enterprise Content Management Library and its companion K-3 Data Encryption© software to government agencies, banks, law firms and mid-to-large size businesses. Marketing these products, which can limit, govern and prevent the download and transmission of confidential repository content, could provide a platform upon which Bulova could realize sustainable growth moving forward.

“Bulova Technologies through this newly formed joint venture will play a major role in cyber security, which is a war with gigantic stakes,” Stephen L. Gurba, president and chief executive officer of Bulova, stated in a news release. “We are pleased to enter into the joint venture… which is owned 30 percent by Bulova… and 70 percent by Blackford Technologies, LLC.”

In June, Bulova built on its recent advancement toward expanding its market potential when it announced the signing of a letter of intent to acquire the Twiss Transport family of businesses, which provide medium-to-long haul refrigerated and dry transportation and storage solutions to customers throughout the continental U.S. This acquisition, which is expected to close later this month, could add an estimated $30 million in annual sales to the company’s financial results in the years to come.

For prospective shareholders, Bulova’s progress toward market diversification could clear the way for strong financial growth in the months ahead. Look for the company to capitalize on the opportunities presented by its recent business activities in order to build upon the success of its established defense and industrial machine operations in the future.

For more information, visit www.bulovatechgroup.com

Advanced Photonix, Inc. (NYSE MKT: API) is a leading supplier of optoelectronic sensors, devices and instruments used by original equipment manufacturers in vital markets around the globe. The company offers three innovative product lines designed to meet the needs of clients across a collection of industries. The Optosolutions line enables the measurement of physical color, including temperature, particular counting, color and fluorescence, for medical and process control applications. API’s high-speed optical receiver (HSOR) products are most commonly used by the telecommunications market in the manufacture of market-specific equipment. The terahertz sensor product line provides nondestructive testing and measurement of subsurface physical properties for the industrial process control market.

In February, API announced an agreement with Luna Innovations, Inc. (NASDAQ: LUNA) to merge the two companies. Founded in 1990, Luna researches, develops and commercializes innovative technologies that drive breakthroughs in a diverse collection of markets – including aerospace, automotive, energy, defense, healthcare and telecommunications.

The combined company, which will maintain the Luna name, is expected to provide a broader market base and a strong balance sheet, along with an opportunity to capitalize on potential operating synergies. When completed, the merger situated the company in a fundamentally improved position to realize financial growth through the utilization of a combined intellectual property portfolio featuring over 200 patents and patent application.

“This merger has created a company with a stronger position as a leader in optical technology and provides improved opportunities for accelerated growth,” My Chung, president and chief executive officer of Luna, stated in a news release. “We look forward to working with the talented team at API as we build a dynamic company with even greater potential.”

At the closing of the merger, API stockholders received shares of Luna common stock at a ratio of 0.31782 shares for each owned share of API common stock. According to a Luna news release, the merger received overwhelmingly positive response from shareholders of both companies. For prospective investors, the broadened industry presence of the combined company could provide a platform upon which to realize strong returns moving forward. Look for API and Luna to leverage their combined strengths in order to promote sustainable market growth in the years to come.

For more information, visit www.advancedphotonix.com or www.lunainc.com

The healthcare industry is in the midst of a substantial shift away from traditional fee-for-service payments, which have historically been associated with excessive and unnecessary care, in favor of value-based options. In January, the Centers for Medicare and Medicaid Services reaffirmed this fact when it announced a goal of having 50 percent of all Medicare payments in alternative payment models by the end of 2018. MIT Holding, Inc. (OTCQB: MITD), a leading provider of post-acute care nationwide, is in a strong position to capitalize on this evolving mindset by providing ambulatory care, in-home intravenous therapies, medical equipment and other recovery needs to help patients avoid unnecessary doctor and hospital visits.

According to a report by Fox Business, the total reduction in overall healthcare spending as a result of ambulatory surgery and therapy options amounts to approximately $2.6 billion annually, and an additional $2.4 billion in savings could be realized if just 50 percent of eligible cases were moved to these non-hospital settings. For MITD, these potential savings could translate into improved financial returns in the coming months. Demand for the company’s low cost, high quality home care is expected to rise as payers realize up to 90 percent savings on infusion services performed in the home instead of the hospital.

The potential market for MITD’s home infusion services is vast. According to Harris Williams & Co., the United States home infusion market is currently valued at $15.9 billion, and continued growth is expected to push the market to $26.7 billion by 2020. In the first quarter of 2015, the company made significant strides toward maximizing its share of this pivotal sector by recording just under $490,000 in consolidated revenues, which was a year-over-year increase of over 133 percent. Leveraging an increase in referrals and the strategic use of subcontractors, MITD also realized a gross profit of nearly $278,000 for the period.

“Our target audience is focused on those needing infusion for recovery,” Tommy Duncan, president of MITD, stated in a news release. “Our platform is based on the delivery of these high cost, specialty pharmaceuticals that have specialized handling and administration requirements.”

For prospective investors, MITD’s strong financial results in recent quarters, as well as the increasing demand for its value-based services, could provide the company with a platform to deliver strong returns moving forward. Look for MITD to continue building on its established position within the ambulatory care market in order to capitalize on rising demand in the years to come.

For more information on MIT Holding, visit www.mitholdinginc.com

Let us hear your thoughts: MIT Holding, Inc. Message Board

ENGlobal recenlty announced that it is one of three companies who will be receiving a multiple-award contract by the U.S. Military for the procurement of automated fuel handling equipment (AFHE) support services. Estimated value of the fixed-price contracts is approximately $215 million. Also, there are prospects that the work could continue to June 2017 if the contract reaches the $215 million figure. Contract factors are contingent upon the U.S. Navy exercising all options.

ENG’s role in the project consists of development, engineering, design, integration, fabrication, logistics, installation, quality assurance, logistics, life-cycle management, maintenance, and technical support for AFHE systems. The primary focus for the company will be on an indefinite-delivery/indefinite-quantity (ID/IQ), cost-plus-fixed-fee contract for technical and maintenance services for automated tank gauging and automated fuel service stations. Work will be performed at the DOD fuel facilities worldwide. Completion date is expected to be by the second quarter 2013.

Edward L. Pagano, ENGlobal’s President and Chief Executive Officer commented, “ENGlobal has a proven track record of delivering exceptional service to SPAWAR since 2007.” “This cumulative award for the three firms represents an increase of approximately $89 million over the 2007 award level of $126 million and, as validated by our performance, we will make every effort to increase ENGlobal’s portion of the base contract funding.”

Mr. Pagano further added, “Our Government Services division, based in Tulsa, Oklahoma, specializes in the turn-key installation and maintenance of automation and instrumentation systems for the U.S. defense industry worldwide. This award demonstrates that our technical capability for AFHE engineering support extends globally to keep Department of Defense fuel systems fully mission capable.”

Further information about the company and its businesses is available at www.ENGlobal.com

In 1996, California became the first state in the country to legalize the use of medical cannabis when it enacted Proposition 215. Less than two decades later, a total of 23 states, as well as the District of Columbia, have legalized marijuana for medicinal purposes, and that progress has come without a single clinical trial taking place. To this point, the medicinal cannabis market has existed without facing many of the regulatory hurdles present in the pharmaceutical industry, but that could be changing soon. With the movement to reclassify cannabis as a schedule II drug at the federal level rapidly gaining steam, the current landscape of the medical cannabis industry could be closing in on a period of transformation.

As a schedule II drug, cannabis could be recognized as a therapeutic treatment with an accepted medical use in the United States, which would dramatically increase the marketability of cannabis-based pharmaceuticals. This shift in perception would likely entice major pharmaceutical players to begin studying the medicinal benefits of marijuana. GrowBLOX Sciences, Inc. (OTCQB: GBLX), through the development and commercialization of its proprietary GrowBLOX technology suite, is prepared to capitalize on this market evolution by providing an unrivalled approach to consistent cannabis production.

The GrowBLOX technology suite was specially engineered to safely and reliably deliver consistent cannabis products by preserving and replicating carefully chosen genetic stock and precisely controlling the growing process. By monitoring everything from lighting conditions and temperature to oxygen and carbon dioxide levels, the company’s innovative products allow for the elimination of many limiting variables in order to maximize the accuracy and consistency of both clinical testing and full-scale production efforts.

In an interview with TNMNews, César Cordero Krüger, chief executive officer of GB Sciences Puerto Rico, provided investors with a detailed look at the vast market potential for GrowBLOX’s groundbreaking cultivation suite as the medical cannabis industry continues to mature. According to Krüger, the epicenter of future medical marijuana production isn’t located in the continental United States, but in the U.S. territory of Puerto Rico.

Puerto Rico’s history as a medical marijuana hub is just beginning. In 2014, Governor Alejandro Garcia Padilla signed an executive order authorizing the manufacturing of medical marijuana across the island. Although details are still under wraps, Krüger highlighted the possibility that the government’s future plans could involve the University of Puerto Rico, giving the local industry access to the university’s molecular science building, cancer research facilities and independent laboratory testing.

With one of the densest concentrations of pharmaceutical industries in the world, Puerto Rico appears to have a major role to play in the future of the medical cannabis industry. Likewise, look for GrowBLOX and its subsidiaries to make waves with the continued development and commercialization of the GrowBLOX technology suite.

For more information, visit www.growblox.com

To listen to the full conversation with César Cordero Krüger, visit www.tnmnews.com

Let us hear your thoughts: GrowBLOX Sciences, Inc. Message Board